Last edition
News about
Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer
Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.
GentiBio Doses First Patient in Phase I Trial of Novel Cell Therapy for Type 1 Diabetes
GentiBio initiates Phase I POLARIS trial of GNTI-122, an engineered Treg therapy aimed at preserving insulin production and reducing lifelong insulin dependence in newly diagnosed type 1 diabetes patients.
Glenmark Pharma USA Introduces Potassium Phosphates Injection USP
Glenmark Pharmaceuticals USA is set to launch Potassium Phosphates Injection USP in March 2026.
Strides Pharma Acquires Sandoz's Generic Brands to Expand African Business
Strides Pharma has acquired multiple generic brands from Sandoz to expand its African business, a move expected to position it among the top five pharma companies in Sub-Saharan Africa and more than double its regional presence.
Samsung Bioepis Partners with Sandoz for Next-Gen Biosimilar Candidates
Samsung Bioepis has partnered with Sandoz to develop and commercialise up to five biosimilar candidates, including SB36 (vedolizumab), across global markets, excluding select Asian regions, strengthening its pipeline in immunology and oncology.
Sanofi Secures FDA Breakthrough Designation for Rare Disease Therapy
Sanofi has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its investigational drug venglustat, aimed at treating neurological symptoms associated with type 3 Gaucher disease (GD3).
Leveragen Teams Up with Daiichi Sankyo for Next-Gen Biologics Innovation
Daiichi Sankyo will collaborate with Leveragen to apply its in-vivo antibody discovery platform across selected research programmes, supporting early-stage and pre-clinical development of antibody-based biologics across multiple therapeutic areas.
Zydus and Torrent Pharma Sign Licensing Deal to Co-Market Semaglutide in India
Zydus Lifesciences and Torrent Pharmaceuticals have entered a licensing agreement to co-market Semaglutide injection in India, aiming to improve access for patients with poorly controlled Type 2 Diabetes Mellitus and support chronic weight management through advanced, innovative therapy.
Mankind Pharma Acquires Rivotril Brand for India, Reinforcing Focus on Chronic CNS Therapies
Mankind Pharma Limited today announced that it has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions.
US FDA Pushes Shift Away from Animal Testing in Early Drug Studies
The U.S. Food and Drug Administration (FDA) is pushing for a shift away from animal testing in early-stage drug development, encouraging companies to adopt more modern and human-relevant methods.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy